(MedPage Today) — Novel anti-ST2 monoclonal antibody astegolimab modestly reduced chronic obstructive pulmonary disease (COPD) exacerbations in the phase IIb ALIENTO trial.
The biologic dosed every 2 weeks reduced moderate or severe COPD exacerbations…
Source link : https://www.medpagetoday.com/meetingcoverage/ers/117682
Author :
Publish date : 2025-09-28 21:04:00
Copyright for syndicated content belongs to the linked Source.
